<?xml version="1.0" encoding="UTF-8"?>
<abstract id="16885182">
  <title>
    <s id="0" section="title">
      Safety and efficacy of
      <group id="0">
        routine  postoperative
        <short>ibuprofen</short>
      </group>
      for pain and disability related to
      <outcome id="2">ectopic  bone  formation</outcome>
      after hip replacement surgery ( HIPAID ) : randomised controlled trial .
    </s>
  </title>
  <annotated>
    <s id="3" section="setting">20 orthopaedic surgery centres in Australia and New Zealand .</s>
    <s id="4" section="participants">
      <ps>902</ps>
      patients undergoing elective primary or revision total hip replacement surgery .
    </s>
    <s id="5" section="intervention">
      <group id="0">
        14  days  '  treatment  with
        <short>ibuprofen</short>
        (  1200  mg  daily  )
      </group>
      or
      <group id="0">matching  placebo</group>
      started within 24 hours of surgery .
    </s>
    <s id="6" section="main_outcome_measures">
      <outcome id="0">
        Changes  in  self  reported
        <short>hip  pain</short>
      </outcome>
      and
      <outcome id="1">
        <short>physical  function</short>
        <time id="0">6  to  12  months  after  surgery</time>
      </outcome>
      ( Western Ontario and McMaster University Arthritis index ) .
    </s>
    <s id="7" section="results">
      There were no significant differences between the groups for
      <outcome id="0">
        improvements  in
        <short>hip  pain</short>
      </outcome>
      ( mean difference - 0.1 , 95 % confidence interval - 0.4 to 0.2 , P = 0.6 ) or
      <outcome id="1">physical  function</outcome>
      ( - 0.1 , - 0.4 to 0.2 , P = 0.5 ) , despite a decreased
      <outcome id="2">
        risk  of
        <short>ectopic  bone  formation</short>
      </outcome>
      ( relative risk 0.69 , 0.56 to 0.83 ) associated with
      <group id="0">ibuprofen</group>
      .
    </s>
  </annotated>
  <fulltext>Safety and efficacy of routine postoperative ibuprofen for pain and disability related to ectopic bone formation after hip replacement surgery ( HIPAID ) : randomised controlled trial . To determine the benefits and risks of a non - steroidal anti - inflammatory drug ( NSAID ) as prophylaxis for ectopic bone formation in patients undergoing total hip replacement ( or revision ) surgery . Double blind randomised placebo controlled clinical trial , stratified by treatment site and surgery ( primary or revision ) . 20 orthopaedic surgery centres in Australia and New Zealand . 902 patients undergoing elective primary or revision total hip replacement surgery . 14 days ' treatment with ibuprofen ( 1200 mg daily ) or matching placebo started within 24 hours of surgery . Changes in self reported hip pain and physical function 6 to 12 months after surgery ( Western Ontario and McMaster University Arthritis index ) . There were no significant differences between the groups for improvements in hip pain ( mean difference - 0.1 , 95 % confidence interval - 0.4 to 0.2 , P = 0.6 ) or physical function ( - 0.1 , - 0.4 to 0.2 , P = 0.5 ) , despite a decreased risk of ectopic bone formation ( relative risk 0.69 , 0.56 to 0.83 ) associated with ibuprofen . There was a significantly increased risk of major bleeding complications n the ibuprofen group during the admission period ( 2.09 , 1.00 to 4.39 ) . These data do not support the use of routine prophylaxis with NSAIDs in patients undergoing total hip replacement surgery . NCT00145730 .</fulltext>
  <ignored>
    <s id="1" section="objectives">
      To determine the benefits and risks of a
      <group id="0">
        <short>non  -  steroidal  anti  -  inflammatory  drug</short>
        (  NSAID  )
      </group>
      as prophylaxis for
      <outcome id="2">ectopic  bone  formation</outcome>
      in patients undergoing total hip replacement ( or revision ) surgery .
    </s>
    <s id="2" section="design">Double blind randomised placebo controlled clinical trial , stratified by treatment site and surgery ( primary or revision ) .</s>
    <s id="8" section="results">
      There was a significantly increased
      <outcome id="3">
        risk  of
        <short>major  bleeding  complications</short>
      </outcome>
      n the
      <group id="0">ibuprofen  group</group>
      during the admission period ( 2.09 , 1.00 to 4.39 ) .
    </s>
    <s id="9" section="conclusions">
      These data do not support the use of
      <group id="0">routine  prophylaxis  with  NSAIDs</group>
      in patients undergoing total hip replacement surgery .
    </s>
    <s id="10" section="trial_registration">NCT00145730 .</s>
  </ignored>
</abstract>

